Clinical trials: Gastric Ulcer
Stress Ulcers, Stress-related Mucosal Disease (SRMD)
China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients
Stress ulcers or stress-related mucosal disease (SRMD) is defined as "acute superficial inflammation lesions of the gastric mucosa induced when an individual is subject to abnormally elevated physiologic demands."[1] Studies have…
- Trial name
- SUP (NCT02316990)
- Where
- 11 sites in China
- Volunteers
- 1,416 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Reflux Esophagitis
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in…
- Trial name
- OMAREE (NCT00859287)
- Volunteers
- 10,703 people
- Sponsor
- AstraZeneca
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00321737
- Testing
- Dexlansoprazole MR
- Where
- 98 sites in United States, Australia and 6 more
- Volunteers
- 445 people
- Sponsor
- Takeda
Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
The purpose of this survey is to evaluate the safety and effectiveness of vonoprazan tablets in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in the routine clinical setting.
- Trial name
- NCT03214952
- Testing
- Vonoprazan
- Where
- Japan
- Volunteers
- 3,183 people
- Sponsor
- Takeda
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Osteoarthritis
Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®
LT-NS001 is a prodrug of Naproxen, which is inactive as a cox inhibitor while intact and is rapidly metabolized to Naproxen once absorbed.
- Trial name
- NCT01063920
- Testing
- LT-NS001, Naprosyn®
- Where
- 65 sites in United States
- Volunteers
- 534 people
- Sponsor
- Logical Therapeutics
Gastric Ulcers, Duodenal Ulcers
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
The purpose of this study is to evaluate the safety of TAK-438, once daily (QD), during long-term concomitant low-dose aspirin therapy in patients with a history of gastric or duodenal ulcer who require long-term therapy of…
- Trial name
- NCT01456247
- Testing
- TAK-438, Lansoprazole
- Where
- 76 sites in Japan
- Volunteers
- 439 people
- Sponsor
- Takeda
Gastric Ulcer
The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
- Trial name
- NCT06902818
- Testing
- AD-115A, AD-1151
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Addpharma Inc.
Esophagitis, Gastroesophageal Reflux
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls). Some PPIs are already commercially available.
- Conditions
- Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
- Trial name
- NCT00284908
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- STEBA France
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Initial Treatment)
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by…
- Trial name
- NCT00633932
- Testing
- Esomeprazole, Omeprazole
- Where
- 41 sites in Japan
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
Peptic Ulcer
Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment
The purpose of this study is to evaluate of efficacy and safety as H.pylori eradiation effect between Ilaprazole and Pantoprazole triple therapy for 7 days treatment in Gastric and/or Duodenal ulcer patients with H.pylori…
- Trial name
- NCT02084420
- Testing
- Ilaprazole, Pantoprazole
- Where
- 18 sites in South Korea
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Reflux Esophagitis
Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
The purpose of this survey is to evaluate the safety and effectiveness of long-term administration of vonoprazan tablets when used as maintenance therapy for reflux esophagitis in routine clinical settings.
- Trial name
- NCT03214081
- Testing
- Vonoprazan
- Where
- Japan
- Volunteers
- 1,237 people
- Sponsor
- Takeda
Osteoarthritis, Peptic Ulcer
A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between lansoprazole, naproxen and celecoxib, taken once…
- Trial name
- NCT00175032
- Testing
- Lansoprazole and naproxen and aspirin, Celecoxib and aspirin
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Osteoarthritis, Rheumatoid Arthritis
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
The purpose of this study is to evaluate the incidence of gastric ulcers following administration of either PN 200 or Naproxen in subjects who are at risk for developing NSAID-associated ulcers.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- NCT00367211
- Testing
- PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- POZEN
Stomach Ulcer
A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium
The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer.
- Trial name
- NCT00125736
- Testing
- E0671, rabeprazole sodium
- Where
- 43 sites in Japan
- Volunteers
- 520 people
- Sponsor
- Eisai Co., Ltd.
Reflux Esophagitis (RE)
A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.
- Trial name
- NCT07010107
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca
Duodenal Ulcer
Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer
This is a multi-center, randomized, double-blind, double-dummy, parallel-group, active-controlled Phase III clinical study to evaluate the efficacy and safety of LXI-15028 50mg comparing with Lansoprazole 30 mg after the…
- Trial name
- NCT05010954
- Testing
- LXI-15028 50mg group, Lansoprazole 30mg group
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.